This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. I just returned
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. Stoke Therapeutics is
SAN DIEGO — The approval one year ago of two genetic medicines for sickle cell disease, including the first therapy powered by CRISPR gene editing,
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. Applied Therapeutics’ CEO
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Happy Tuesday! Adam Feuerstein,
Four years on, the Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s disease, simufilam,
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. Biotech
Kura Oncology has signed a global partnership with the Japanese drugmaker Kyowa Kirin to develop and sell Kura’s experimental treatment for acute leukemia, the companies
The Food and Drug Administration approved on Friday a new drug developed by Syndax Pharmaceuticals to treat patients with a genetically defined form of advanced
Regenxbio reported Monday the first clinical evidence showing improved muscle function in boys with Duchenne muscular dystrophy following treatment with its experimental gene therapy. The